In this regard, it is correct to point out that patients with symptomatic MEN1 gastrinomas, a long-time treatment by H2-blockers or PPIs, may stimulate gastric neuroendocrine cells proliferation contributing to the clinical outcome and severity of GEP-NETs (194). The gene discussed is MEN1; the disease is gastrin-producing neuroendocrine tumor.